

Gallbladder bile formation

Mechanism of gallbladder bile formation

Two points in the process of gallbladder bile formation should be distinguished: 1) in a fasting stomach; 2) after postprandial gallbladder emptying (1). The absorbing and concentrating functions determine the mechanism of the gallbladder bile formation.

The rate of biliary cholesterol absorption by the gallbladder mucosa depends on the concentration of the cholesterol in the gallbladder bile ($r = +0.60$, $p < 0.001$) (2-4). Taking into account the fact that the mixed (bile acids-phospholipid-cholesterol) micelles are not absorbed by the gallbladder mucosa, cholesterol can be absorbed as monomers or with phospholipid vesicles (1-9). The solubility of anhydrous cholesterol monomers in water is 0.013 nmol/ml, in the intermicellar phase – 0.260 nmol/ml, while in phospholipid vesicles – 5.5 $\mu\text{mol/ml}$ (10-15). Therefore, according to the solubility of anhydrous cholesterol, it will be absorbed with the phospholipid vesicles to a greater degree (99.9%). The phospholipid vesicles can be absorbed by the gallbladder mucosa in different ways (1, 8, 9, 16-19). Therefore, the greater is the absorption of vesicular cholesterol by the gallbladder mucosa, the lower is the concentration of the cholesterol in the phospholipid vesicles of the gallbladder bile.




Fig. 4a. Exchange of cholesterol and bile acids in healthy humans.

1 = synthesis of cholesterol;
 2 = synthesis of cholesterol esters for VLDL;
 3 = hydrolysis of cholesterol esters entered the hepatocytes with HDL and LDL, and hydrolysis of cholesterol esters entered the hepatocytes with CMR;
 4 = synthesis of bile acids.
 ChE = cholesterol esters;
 ChA = cholesterol anhydrous;
 ChM = cholesterol monohydrate;
 BA = bile acids; HA = hepatic artery;
 HV = hepatic vein; PV = portal vein;
 LD = lymphatic duct.

The concentration function of the gallbladder consists in the accumulation of the bile acids of the hepatic bile in the gallbladder; it depends on the rate of bile acids of the hepatic bile entering the gallbladder and the rate of water absorption by the gallbladder mucosa, and it also determines the concentration of the total bile acids and the formation of mixed biliary micelles in the gallbladder bile (fig. 4a). In hepatic bile 40-80% of biliary cholesterol is in phospholipid vesicles and 20-60% of it is in mixed biliary micelles (15, 20, 21). The gallbladder, concentrating the bile acids, forms mixed biliary micelles and raises the level of biliary cholesterol in them up to 80-100% (15, 20, 21).

Therefore, the greater is the absorption of water by the gallbladder mucosa, the greater is the passage of bile acids of hepatic bile to the gallbladder and the higher is the concentration of total bile acids in the gallbladder bile.

Thus, the high concentration of the total bile acids and the low concentration of cholesterol in phospholipid vesicles result in the low cholesterol saturation index in the gallbladder bile (less than 1.0), which determines the stability of micellar carriers of biliary cholesterol and prevents the cholesterol monohydrate crystals from precipitating.

Fate of the absorbed vesicular biliary cholesterol

Part of the absorbed cholesterol may be esterified in the epithelial cells of gallbladder mucosa by means of ACAT. Normally the activity of ACAT makes up 92 ± 23 pmol/min per mg protein and is 8-9 times as high as that of microsomes of the liver (11 ± 2 pmol/min per mg protein) (22). There is a positive correlation between the concentration of the cholesterol in the gallbladder bile and ACAT in microsomes of gallbladder mucosa ($r = +0.42$, $p < 0.05$). The cholesterol is also synthesized in the microsomes of gallbladder mucosa, and the activity of HMG-CoA reductase in them makes up 28 ± 6 pmol/min per mg protein. But it is 4 times lower, than that in the microsomes of hepatocytes (120 ± 40 pmol/min per mg protein). The concentration of free cholesterol in the microsomes of gallbladder mucosa (206 ± 9 nmol/min per mg protein) is 4 times higher than that in microsomes of hepatocytes (55 ± 3 nmol/min per mg protein), while the concentration of esterified cholesterol (34 ± 5 nmol/min per mg protein) is 3.5 times higher (9 ± 1 nmol/min per mg protein) (22). Taking into account the low activity of HMG-CoA reductase and the high activity of ACAT in the microsomes of gallbladder mucosa, as well as the positive correlation between the level of cholesterol in the gallbladder bile and the microsomes of gallbladder mucosa ($r = +0.75$, $p < 0.01$), the higher concentration of free cholesterol in the microsomes of epithelial cells of gallbladder mucosa may result only from the excessive absorption of the biliary vesicular cholesterol. It testifies that the rate of the biliary vesicular cholesterol entering the epithelial cells of gallbladder mucosa 4 times exceeds that of hepatocytes.




Fig. 4b. Exchange of cholesterol in healthy humans.

1 = Gallbladder-dependent output of biliary cholesterol; 2 = gallbladder-independent output of biliary cholesterol; 3 = gallbladder-hepatic circulation of biliary cholesterol; 4 = hydrolysis of cholesterol esters entered the hepatocytes with HDL and LDL; 5 = synthesis of cholesterol; 6 = synthesis of cholesterol esters for VLDL; 7 = hydrolysis of cholesterol esters entered the hepatocytes with CMR.

ChA = cholesterol anhydrous; ChM = cholesterol monohydrate; HA = hepatic artery; HV = hepatic vein; PV = portal vein; LD = lymphatic duct.

By analogy with ileum, the removal of the absorbed vesicular cholesterol and phospholipids from the gallbladder wall may be realized by means of HDL and/or VLDL (17, 18, 23-25). It was shown in vitro that HDL are able to extract the excess of cholesterol out of cholesterol-saturated phospholipid vesicles and to dissolve the cholesterol crystals (26, 27). It is possibly that the mechanism of the removal of the absorbed vesicular cholesterol and phospholipids by means of HDL may be prevalent and it may be determined by the concentration of HDL in serum and by the rate of the arterial bloodstream in the gallbladder wall (28, 29). In the gallbladder wall HDL, interrelating with phospholipid vesicles, will extract biliary vesicular cholesterol and phospholipids and, with bloodstream, will first enter the gallbladder vein and then, through the portal vein, the liver (fig. 4b).

This supposition is indirectly corroborated by the negative correlative connection between CSI and the level of the total cholesterol (TCh) ($r = .065$, $p < 0.05$) and Ch-HDL ($r = .062$, $p < 0.05$) in the serum in practically healthy women (30). In the gallbladder mucosa, small quantities of VLDL synthesize (31). The number of apoproteins B, C-II and C-III absorbed by the gallbladder mucosa can make up 84-91% of total quantity of apoproteins B, C-II and C-III, entering the gallbladder with

the hepatic bile (32). Also, taking into account that the mucosa of the gallbladder absorbs phospholipid vesicles, apoproteins B, C-II and C-III, they can interrelate with serum HDL, LDL, and VLDL in the gallbladder wall below epithelium.

The absorbed vesicular cholesterol of gallbladder mucosa, interrelating with blood lipoproteins, can enter the liver or the peripheral blood stream through the portal vein (fig. 4.a). The way of biliary cholesterol [blood (lipoproteins) → liver (hepatic bile – phospholipid vesicles) → gallbladder (absorption of vesicular cholesterol) → portal vein (lipoproteins) → liver or blood] – was called by us “gallbladder-hepatic circulation of biliary cholesterol” (fig. 4.a). The detailed structuring of these processes provides an opportunity to connect the excretory function of the liver and the absorption and evacuation functions of the gallbladder with the level of cholesterol in serum.

References:

1. Turumin JL, Shanturov VA. The disturbance of the gallbladder bile formation in-patients with cholesterol gallstone disease. XIV International Bile Acid Meeting (Falk Symposium 93), 1996: A105.
2. Jacyna MR, Ross PE, Bakar MA, Hopwood D, Bouchier IAD. Characteristics of cholesterol absorption by human gallbladder: relevance to cholesterosis. *J Clin Pathol* 1987; **40**: 524-529.
3. Jacyna MR. Interactions between gallbladder bile and mucosa: relevance to gallstone formation. *Gut* 1990; **31**: 586-570.
4. Ross PE, Butt AN, Gallacher C. Cholesterol absorption by the gallbladder. *J Clin Pathol* 1990; **43**: 572-575.
5. Ginanni Corradini S, Ripani C, Della Guardia P, Giovannelli L, Elisei W, Cantafora A, Pisanelli MC, Tebala GD, Nuzzo G, Corsi A, Attili AF, Capocaccia L, Ziparo V. The human gallbladder increases cholesterol solubility in bile by differential lipid absorption: a study using a new in vitro model of isolated intra-arterially perfused gallbladder. *Hepatology* 1998; **28**: 314-322.
6. Ginanni Corradini S, Yamashita G, Nuutinen H, Chernosky A, Williams C, Hays L, Shiffman ML, Walsh RM, Svanvik J, Della Guardia P, Capocaccia L, Holzbach RT. Human gallbladder mucosal function: effects on intraluminal fluid and lipid composition in health and disease. *Dig Dis Sci* 1998; **43**: 335-343.
7. Ginanni Corradini S, Elisei W, Giovannelli L, Ripani C, Della Guardia P, Corsi A, Cantafora A, Capocaccia L, Ziparo V, Stipa V, Chirletti P, Caronna R, Lomanto D, Attili AF. Impaired human gallbladder lipid absorption in cholesterol gallstone disease and its effect on cholesterol solubility in bile. *Gastroenterology* 2000; **118**: 912-920.
8. Koga A. Fine structure of the human gallbladder with cholesterosis with special reference to the mechanism of lipid accumulation. *Brit J Exp Pathol* 1985; **66**: 605-611.
9. Secknus R, Darby GH, Chernosky A, Juvonen T, Moore EW, Holzbach RT. Apolipoprotein A-I in bile inhibits cholesterol crystallization and modifies transcellular lipid transfer through cultured human gallbladder epithelial cells. *J Gastroenterol Hepatol* 1999; **14**: 446-456.
10. Loomis CR, Shipley GG, Small DM. The phase behavior of hydrated cholesterol. *J Lipid Res* 1979; **20**: 525-535.
11. Chijiwa K, Kiyosawa R, Nakayama F. Cholesterol monomer activity correlates with nucleation time in model bile. *Clin Chim Acta* 1988; **178**: 181-192.
12. Chijiwa K, Nagai M. Interaction of bile salt monomer and cholesterol in the aqueous phase. *Biochim Biophys Acta* 1989; **1001**: 111-114.
13. Chijiwa K, Nagai M. Bile salt micelle can sustain more cholesterol in the intermicellar aqueous phase than the maximal aqueous solubility. *Arch Biochem Biophys* 1989; **270**: 472-477.
14. Chijiwa K, Hirota I, Noshiro H. High vesicular cholesterol and protein in bile are associated with formation of cholesterol but not pigment gallstones. *Dig Dis Sci* 1993; **38**: 161-166.
15. Lee SP, Park HZ, Madani H, Kaler EW. Partial characterization of a nonmicellar system of cholesterol solubilization in bile. *Amer J Physiol* 1987; **252**: G374-G384.
16. Sewell RB, Mao SJT, Kawamoto T, LaRusso NF. Apolipoproteins of high, low, and very low density lipoproteins in human bile. *J Lipid Res* 1983; **24**: 391-401.
17. Klimov AN, Nikulcheva NG. Lipid and lipoprotein metabolism and its disorders. St. Petersburg: Piter Publishing, 1998: 222-237.
18. Cooper AD. Plasma lipoprotein metabolism. In: Fromm H, Leuschner U, editors. Bile Acids-Cholestasis-Gallstones. Advances in Basic and Clinical Bile Acid Research. Dordrecht: Kluwer, 1996: 97-126.

19. **Miettinen TA**, Kesaniemi YA. **Cholesterol** absorption: regulation of cholesterol synthesis and elimination and within-population variations of serum cholesterol levels. *Amer J Clin Nutr* 1989; **49**: 629-635.
20. **Del Pozo R**, He C, Meyer G, Muller I, Frimberger E, Jungst D. Correlation of **cholesterol** in vesicles to total protein and the relevance of protein-lipid interaction in gallbladder bile of patients with gallstones. *Gastroenterology* 1997; **112**: 502.
21. **Eckhardt ER**, van de Heijning BJ, van Erpecum KJ, Renooij W, Van Berge Henegouwen GP. **Quantitation of cholesterol-carrying particles in human gallbladder bile**. *J Lipid Res* 1998; **39**: 594-603.
22. **Sahlin S**, Ahlberg J, Reihnr E, Stahlberg D, Einarsson K. **Cholesterol** metabolism in human gallbladder mucosa: relationship to cholesterol gallstone disease and effects of chenodeoxycholic acid and ursodeoxycholic acid treatment. *Hepatology* 1992; **16**: 320-326.
23. **Cooper AD**. **Metabolic basis of cholesterol** gallstone disease. *Gastroenterol Clin North Amer* 1991; **20**: 21-46.
24. **Glickman RM**, Sabesin SM. **Lipoprotein metabolism**. In: Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA, editors. *The Liver, Biology and Pathobiology*. 3rd ed. New York: Raven Press, 1994: 391-414.
25. **Kesaniemi YA**, Miettinen TA. **Metabolic epidemiology of plasma cholesterol**. *Ann Clin Res* 1988; **20**: 26-31.
26. **Jonas A**, Hesterberg LK, Drenkler SM. **Incorporation of excess cholesterol** by high-density serum lipoproteins. *Biochim Biophys Acta* 1978; **528**: 47-57.
27. **Adams CWM**, Abdula YH. **The action of human HDL on cholesterol** crystals. *Atherosclerosis* 1978; **31**: 464-471.
28. **Turumin JL**, Shanturov VA, Chikotejev SP, Tarabrin AL. **The low level of Ch-HDL as a risk factor for cholesterol** gallstone disease. XIV International Bile Acid Meeting (Falk Symposium 93), 1996: 106.
29. **Della Guardia P**, Grossi A, Elisei W, Eramo A, de Santis A.D, Attili AF, Genco A, Basso N, Ginanni Corradini S. **Plasma lipoproteins affect rate of cholesterol** absorbed from bile by gallbladder: preliminary data. *Ital J Gastroenterol Hepatol* 1999; **31**: 587-592.
30. **Cavallini A**, Messa C, Mangini V, Argese V, Misciagna G, Giorgio I. **Serum and bile lipids in young women with radiolucent gallstones**. *Am J Gastroenterology* 1987; **82**: 1279-1282.
31. **Tilvis RS**, Aro J, Strandberg TE, Lempinen M, Miettinen TA. **In vitro synthesis of triglycerides and cholesterol** in human gallbladder mucosa. *Scand J Gastroenterology* 1982; **17**: 335-340.
32. **Carey MC**, Hernell O. **Digestion and absorption of fat**. *Semin Gastrointestinal Dis* 1992; **3**: 189-208.